TY - JOUR
T1 - Novel culture system of mesenchymal stromal cells from human subcutaneous adipose tissue
AU - Iwashima, Shigejiro
AU - Ozaki, Takenori
AU - Maruyama, Shoichi
AU - Saka, Yousuke
AU - Kobori, Masato
AU - Omae, Kaoru
AU - Yamaguchi, Hirotake
AU - Niimi, Tomoaki
AU - Toriyama, Kazuhiro
AU - Kamei, Yuzuru
AU - Torii, Shuhei
AU - Murohara, Toyoaki
AU - Yuzawa, Yukio
AU - Kitagawa, Yasuo
AU - Matsuo, Seiichi
PY - 2009/5/1
Y1 - 2009/5/1
N2 - Accumulating evidence suggests that the delivery of human adipose tissue-derived stromal cells (hASCs) has great potential as regenerative therapy. This was performed to develop a method for expanding hASCs by reducing the amount of serum required. We demonstrate that hASCs were able to expand efficiently in media containing 2% serum and fibroblast growth factor-2. These cells, or low serum cultured hASCs (hLASCs), expressed cell surface markers similar to those on bone marrow-derived mesenchymal stem cells, and could be differentiated into cells of mesenchymal lineage. Of interest, hLASCs secreted higher levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) than hASCs cultured in 20% serum (hHASCs). Moreover, hLASC-conditioned media significantly increased endothelial cell (EC) proliferation and decreased EC apoptosis compared to that obtained from hHASCs or control media only. Antibodies against VEGF and HGF virtually negated these effects. When hASCs were administered into the ischemic hindlimbs of nude rats, hLASCs improved blood flow, increased capillary density, and raised the levels of VEGF and HGF in the muscles as compared with hHASCs. In conclusion, we demonstrate a novel low serum culture system for hASCs, which may have great potential in regenerative cell therapy for damaged organs in the clinical setting.
AB - Accumulating evidence suggests that the delivery of human adipose tissue-derived stromal cells (hASCs) has great potential as regenerative therapy. This was performed to develop a method for expanding hASCs by reducing the amount of serum required. We demonstrate that hASCs were able to expand efficiently in media containing 2% serum and fibroblast growth factor-2. These cells, or low serum cultured hASCs (hLASCs), expressed cell surface markers similar to those on bone marrow-derived mesenchymal stem cells, and could be differentiated into cells of mesenchymal lineage. Of interest, hLASCs secreted higher levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) than hASCs cultured in 20% serum (hHASCs). Moreover, hLASC-conditioned media significantly increased endothelial cell (EC) proliferation and decreased EC apoptosis compared to that obtained from hHASCs or control media only. Antibodies against VEGF and HGF virtually negated these effects. When hASCs were administered into the ischemic hindlimbs of nude rats, hLASCs improved blood flow, increased capillary density, and raised the levels of VEGF and HGF in the muscles as compared with hHASCs. In conclusion, we demonstrate a novel low serum culture system for hASCs, which may have great potential in regenerative cell therapy for damaged organs in the clinical setting.
UR - http://www.scopus.com/inward/record.url?scp=67649277717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649277717&partnerID=8YFLogxK
U2 - 10.1089/scd.2008.0358
DO - 10.1089/scd.2008.0358
M3 - Article
C2 - 19055360
AN - SCOPUS:67649277717
SN - 1547-3287
VL - 18
SP - 533
EP - 543
JO - Stem Cells and Development
JF - Stem Cells and Development
IS - 4
ER -